Literature DB >> 16868820

Predictors of clinical response to systemic steroids in active ulcerative colitis.

Isabel Bernal1, Míriam Mañosa, Eugeni Domènech, Esther Garcia-Planella, Mercè Navarro, Vicente Lorenzo-Zúñiga, Eduard Cabré, Miquel Angel Gassull.   

Abstract

Although systemic steroids remain as the gold standard for the treatment of acute moderate to severe active ulcerative colitis (UC), 15-57% of patients do not achieve clinical remission. We sought to identify clinical, biological, or radiologic predictive factors of response to steroid treatment in acute UC attacks. The medical records of 39 consecutive patients admitted for an acute attack of UC and treated with systemic steroids, were reviewed. Epidemiologic, demographic, and clinical data at baseline and clinical data 3 days after starting steroid treatment were registered. Treatment failure was defined as the need of IV cyclosporine or colectomy before hospital discharge. Twenty-four patients (62%) responded to systemic steroids. Thirteen out of the 15 nonresponders, were treated with IV cyclosporine, avoiding colectomy in 7 cases (54%). More than six bowel movements per day at the third day of treatment, blood in stools in the third day of therapy, extensive UC, and the presence of malnutrition were associated with steroid treatment failure, but only blood in stools (P=.04), and more than six movements per day (P=.012) after 3 days of treatment, were found to be independent predictive factors of steroid refractoriness. In conclusion, clinical evaluation 3 days after starting systemic steroids seems to be the best tool to assess short-term prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868820     DOI: 10.1007/s10620-006-9103-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study.

Authors:  W J Sandborn; C J Landers; W J Tremaine; S R Targan
Journal:  Mayo Clin Proc       Date:  1996-05       Impact factor: 7.616

2.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

3.  Cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  R Vega; X Bertrán; M Menacho; E Domènech; V Moreno de Vega; M Hombrados; E Cabré; I Ojanguren; M A Gassull
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

4.  Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial.

Authors:  S Meyers; P K Lerer; E J Feuer; J W Johnson; H D Janowitz
Journal:  J Clin Gastroenterol       Date:  1987-02       Impact factor: 3.062

5.  Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis.

Authors:  E Domènech; E Garcia-Planella; I Bernal; M Rosinach; E Cabré; L Fluvià; J Boix; M A Gassull
Journal:  Aliment Pharmacol Ther       Date:  2002-12       Impact factor: 8.171

6.  Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.

Authors:  M Cottone; G Pietrosi; G Martorana; A Casà; G Pecoraro; L Oliva; A Orlando; M Rosselli; A Rizzo; L Pagliaro
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

7.  Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease.

Authors:  D G Forcione; M J Rosen; J B Kisiel; B E Sands
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

8.  Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis.

Authors:  S C Lindgren; L M Flood; A F Kilander; R Löfberg; T B Persson; R I Sjödahl
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-10       Impact factor: 2.566

9.  Small bowel gas in severe ulcerative colitis.

Authors:  C N Chew; D J Nolan; D P Jewell
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

10.  Intensive intravenous treatment of ulcerative colitis.

Authors:  G Järnerot; P Rolny; H Sandberg-Gertzén
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

View more
  4 in total

Review 1.  Dietary management of IBD--insights and advice.

Authors:  Emma P Halmos; Peter R Gibson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

2.  Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis.

Authors:  Han Ho Jeon; Hyun Jung Lee; Hui Won Jang; Jin Young Yoon; Yoon Suk Jung; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

3.  Glucocorticoid treatment, immobility, and constipation are associated with nutritional risk.

Authors:  Jean-Pierre Gutzwiller; Josef Aschwanden; Samuel Iff; Michèle Leuenberger; Martin Perrig; Zeno Stanga
Journal:  Eur J Nutr       Date:  2011-03-03       Impact factor: 5.614

Review 4.  Steroid-refractory severe ulcerative colitis: what are the available treatment options?

Authors:  Alan C Moss; Mark A Peppercorn
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.